A director at Samsung Biologics Co Ltd sold 195 shares at 1,011,000.000KRW and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
We have calculated the significant supply about to enter the biologics manufacturing space & analysed demand growth. Whilst the market assumes an improvement in utilisation from 2024, we forecast there will be significant overcapacity in the coming years resulting in even lower utilisation at an industry level. Our detailed bottom-up analysis shows that total mammalian cell supply is set to grow by 11% p.a. 2023-26 but demand is set to grow just 8% p.a. over the same period. However, much more c...
The independent financial analyst theScreener just lowered the general evaluation of SAMSUNG BIOLOGICS (KR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 7, 2022, the closing price was KRW 844,000.00 and its ...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Joint Global coordinators aim to raise around US$125m via selling shares in Pharmaron in order to aid certain convertible bond investors to hedge their exposure. We have earlier looked at the company’s H-share listing in 2019. Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading In this note...
Whilst most people consider the US election outcome as the most important event this week, for millions of Alzheimer’s (AD) patients & their families, the Aducanumab FDA AdCom on Friday is likely to be more impactful. Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact of a potential AD windfall from Biogen’s aducanumab. We believe Biogen will already have a shortlist of CDMO suppliers as we show they can only produce ~25% of the quantity required & the FDA will ...
FYB201 (BS auf „Lucentis ®“ – 2019er US-Jahresumsatz $ 2,1 Mrd.) ist (wie auch FYB202) ein reines Royalty-Programm, ohne Meilensteine. Einnahmen daraus fließen – später und wohl auch spärlicher (s.u.) als ursprünglich angenommen - ab 21/22e. Die EQUI.TS-Schätzung wird abgesenkt. Zu den Lucentis ®-BS-Entwicklern Samsung Bioepis ist im Mai ein weiteres Entwickler Konsortium dazugekommen. Bis Q1/21 sollen deren Ph3-Topline-Daten vorliegen.
Global Rally Losing Upside Momentum The global rally appears to be losing steam as the bearish rising wedge patterns we highlighted last week in the MSCI ACWI, ACWI ex-US, EM, and EAFE indexes ended up breaking down. Additionally, the aforementioned indexes and major indexes in Europe, Japan, and Hong Kong have been unable to break above longer-term resistance. While we believe global equities remain vulnerable to a pullback, some near-term consolidation is another possibility. For now we belie...
Whilst the market is expecting a near-term peak in cases in Europe, we show that there are likely to be continual outbreaks into 2021 and we will likely see ongoing economic disruption for many quarters to come. HK & Taiwan eased some of the social distancing measures and saw a marked increase in COVID-19 cases. The UK govt’s base case is for continual outbreaks. We show that ICU beds are the limiting factor & driving govt behaviours, not economic disruption. Crucially, we show that looking at...
Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Bio...
- We maintain BUY on Samsung BioLogics given the prospect of rising biologics CMO demand in the mid/long term and the expected normalization of its plant 3 facility in 4Q18. We adjust up our target price from KRW510,000 to KRW680,000 considering the following: 1) global biologics CMO/biosimilar peer multiples remain high; 2) subsidiary Samsung Bioepis’s key pipeline drug obtained a European sales license; and 3) the value of SAIT101 developed by Archigen Biotech, its JV with AstraZeneca,...
NEW YORK--(BUSINESS WIRE)-- Samsung BioLogics (KRX:207940), a leading biopharmaceutical cGMP manufacturing company based in South Korea, is pleased to announce that it has been recognized as a CMO Leadership Awards winner presented by Life Science Leader magazine for the fourth consecutive year since 2013. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170322006390/en/ Samsung BioLogics (KRX:207940), a leading biopharmaceutical cGMP manufacturing company based in South Korea,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.